Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer
Frontiers in Oncology · 28.05.2026 · 16
DOI: 10.3389/fonc.2026.1821704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 28.05.2026. Verfasst von Hang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Kaifeng Central Hospital, Kaifeng, Henan, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The aim of this study was to assess the clinical utility of serum circulating microRNA-21 (miR-21) in the early diagnosis of breast cancer (BC), and to compare its diagnostic performance with raditional serum biomarkers, vascular endothelial growth factor (VEGF) and carbohydrate antigen 15-3 (CA15-3).
Methods
From January 2023 to October 2025, a total of 106 women diagnosed with BC, 69 women with benign breast nodules, and 62 healthy women undergoing routine physical examinations were enrolled at a single institution. Serum levels of miR-21, VEGF, and CA15-3 were measured and compared across groups. Relationships between miR-21 and the traditional markers were analyzed using Spearman correlation analysis. Diagnostic efficacy was assessed via receiver operating characteristic (ROC) curve analysis.
Results
Relative expression levels of serum miR-21, VEGF, and CA15-3 were significantly elevated in individuals with BC compared to healthy controls (all p <0.05). Serum miR-21 and CA15-3 levels were significantly higher in the BC group than in the benign nodule group (both p <0.05). No significant correlations were observed between miR-21 and VEGF (r = –0.032, p =0.747) or CA15-3 (r = –0.068, p =0.487) in the BC cohort. ROC curve analysis demonstrated that miR-21 had an area under the curve (AUC) of 0.897 for distinguishing BC from healthy individuals, with a sensitivity of 81.10% and a specificity of 98.40% at a cut-off value of 1.36. When differentiating BC from benign nodules, the AUC was 0.842, with a sensitivity of 76.40% and specificity of 98.60% at a cut-off value of 1.52. The diagnostic performance of miR-21 exceeded that of VEGF and CA15-3.
Conclusion
Serum circulating miR-21 demonstrated significantly elevated expression in patients with BC and presented superior sensitivity and specificity compared to VEGF and CA15-3. These findings highlight miR-21 as a promising non-invasive biomarker for early breast cancer detection, particularly in distinguishing benign from malignant lesions, potentially reducing unnecessary biopsies. However, limitations include a relatively small sample size and single-center design, necessitating validation in larger, multicenter prospective cohorts. Future studies should explore miR-21’s association with molecular subtypes and clinical outcomes to facilitate clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Kaifeng Central Hospital, Kaifeng, Henan, China.
- Key Laboratory of Tumor Biomarker Detection of Kaifeng, Kaifeng, Henan, China.
- Oncology Department, Kaifeng Central Hospital, Kaifeng, Henan, China.
- Breast and Thyroid Department, Kaifeng Central Hospital, Kaifeng, Henan, China.
Zitieren
APA
Li, H., Li, Q., Tie, X., Ji, F., Ma, L., & Ma, C. (2026). Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1821704
Vancouver
Li H, Li Q, Tie X, Ji F, Ma L, Ma C. Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1821704
BibTeX
@article{Li2026,
author = {Li, Hang and Li, Qian and Tie, Xiaojing and Ji, Feng and Ma, LiNa and Ma, Chunyan},
title = {Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1821704}
}
EUVIMED